Subtitle
Proton Beam Therapy for Histologically or Clinically Diagnosed Stage I Non-small Cell Lung Cancer (NSCLC): The First Nationwide Retrospective Study in Japan.
Subtitle
Proton Beam Therapy for Histologically or Clinically Diagnosed Stage I Non-small Cell Lung Cancer (NSCLC): The First Nationwide Retrospective Study in Japan.
Proto therapy Time
October 2019
Executive summary
Six hundred sixty-nine patients with 682 tumors with histologically or clinically diagnosed Stage I NSCLC who received passive-scattering PBT in Japan were retrospectively reviewed to analyze survivals, local control, and toxicities. This study found that the 3-year overall survival (OS) and progression-free survival (PFS) rates for all patients were 79.5% and 64.1%.
The incidence of Grade 2, 3, 4, and 5 pneumonitis was 9.8%, 1.0%, 0%, and 0.7%, respectively. The incidence of Grade ≥3 dermatitis was 0.4%. No Grade 4 or severe adverse events, other than pneumonitis, were observed. This study concluded that PBT appears to yield acceptable survival rates, with a low rate of toxicities.
Top cancer treatments
Related contents
Proton Therapy Publication
June 2024
Proton and carbon ion radiotherapy for operable early-stage lung cancer; a prospective nationwide registry.
Proton Therapy Publication
July 2024
A Pilot Trial of Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable Non-Small Cell Lung Cancer with Extended Durvalumab Therapy (PARTICLE-D).
Proton Therapy Publication
August 2024
Sparing of the heart facilitates recovery from cardiopulmonary side effects after thoracic irradiation.
Proton Therapy Publication
August 2024
Parallel explorations in LA-NSCLC: Chemoradiation dose-response optimisation considering immunotherapy and cardiac toxicity sparing.
Proton Therapy Publication
April 2024
A bibliometric analysis of cardiotoxicity in cancer radiotherapy.
Proton Therapy Publication
March 2024
FLASH radiotherapy for the treatment of symptomatic bone metastases in the thorax (FAST-02): protocol for a prospective study of a novel radiotherapy approach.
Proton Therapy Publication
February 2024
Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer.
Proton Therapy Publication
April 2024
Long-term survival outcomes and quality of life of image-guided proton therapy for operable stage I non-small cell lung cancer: A phase 2 study.
Proton Therapy Publication
January 2024
Proton and photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and adjuvant immune therapy.